{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:24:26Z","timestamp":1789424666188,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T00:00:00Z","timestamp":1511136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"ImmusanT Inc."}],"content-domain":{"domain":["ebiomedicine.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.ebiom.2017.11.018","type":"journal-article","created":{"date-parts":[[2017,11,23]],"date-time":"2017-11-23T04:16:36Z","timestamp":1511410596000},"page":"78-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study"],"prefix":"10.1016","volume":"26","author":[{"given":"A. James M.","family":"Daveson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hooi C.","family":"Ee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane M.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaela E.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Dzuris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"MacDougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie J.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Treohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Cooreman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0764-7267","authenticated-orcid":false,"given":"Robert P.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2017.11.018_bb0005","article-title":"Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes","volume":"9","author":"Alhadj","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ebiom.2017.11.018_bb0010","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.coi.2013.02.004","article-title":"Vaccine against autoimmune disease: antigen-specific immunotherapy","volume":"25","author":"Anderson","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ebiom.2017.11.018_bb0015","doi-asserted-by":"crossref","first-page":"S437","DOI":"10.1016\/S0016-5085(11)61794-0","article-title":"A phase I study to determine safety, tolerability and bioactivity of Nexvax2 in HLA DQ2+ volunteers with celiac disease following a long-term, strict gluten-free diet","volume":"140","author":"Brown","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ebiom.2017.11.018_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2013.01.049","article-title":"Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology\/European Academy of Allergy and Clinical Immunology\/PRACTALL consensus report","volume":"131","author":"Burks","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ebiom.2017.11.018_bb0025","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1038\/ncomms5741","article-title":"Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy","volume":"5","author":"Burton","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ebiom.2017.11.018_bb0030","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/00007890-199004000-00009","article-title":"In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids","volume":"49","author":"Chatenoud","year":"1990","journal-title":"Transplantation"},{"key":"10.1016\/j.ebiom.2017.11.018_bb0035","first-page":"S304","article-title":"A single intradermal (ID) injection of Nexvax2, a peptide composition with dominant epitopes for gluten-reactive CD4+ T cells, activates T cells and tiggers acute gastrointestinal symptoms in HLA-DQ2.5+ people with celiac disease (CeD)","volume":"150","author":"Goel","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ebiom.2017.11.018_bb0040","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S2468-1253(17)30110-3","article-title":"Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies","volume":"2","author":"Goel","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ebiom.2017.11.018_bb0045","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1084\/jem.189.12.1885","article-title":"Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions","volume":"189","author":"Haselden","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ebiom.2017.11.018_bb0050","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00394-015-1062-3","article-title":"Intake and sources of gluten in 20- to 75-year-old Danish adults: a national dietary survey","volume":"56","author":"Hoppe","year":"2017","journal-title":"Eur. J. Nutr."},{"key":"10.1016\/j.ebiom.2017.11.018_bb0055","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0198-8859(03)00027-2","article-title":"HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease","volume":"64","author":"Karell","year":"2003","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.ebiom.2017.11.018_bb0060","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1021\/jf305122s","article-title":"Can an increase in celiac disease be attributed to an increase in the gluten content of wheat as a consequence of wheat breeding?","volume":"61","author":"Kasarda","year":"2013","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ebiom.2017.11.018_bb0065","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1001\/jamainternmed.2016.5254","article-title":"Time trends in the prevalence of celiac disease and gluten-free diet in the US population: results from the National Health and Nutrition Examination Surveys 2009-2014","volume":"176","author":"Kim","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.ebiom.2017.11.018_bb0070","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1080\/17512433.2016.1200463","article-title":"Current and novel therapeutic strategies in celiac disease","volume":"9","author":"Kurada","year":"2016","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ebiom.2017.11.018_bb0075","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1038\/nm1226","article-title":"Peptide-based therapeutic vaccines for allergic and autoimmune diseases","volume":"11","author":"Larche","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.ebiom.2017.11.018_bb0080","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.cgh.2008.12.032","article-title":"A simple validated gluten-free diet adherence survey for adults with celiac disease","volume":"7","author":"Leffler","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ebiom.2017.11.018_bb0085","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1136\/gutjnl-2013-306578","article-title":"Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology","volume":"63","author":"Ludvigsson","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.ebiom.2017.11.018_bb0090","first-page":"3","article-title":"Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4(+) T cells tolerized by peptide immunotherapy","volume":"29","author":"McPherson","year":"2014","journal-title":"elife"},{"key":"10.1016\/j.ebiom.2017.11.018_bb0095","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1126\/science.133.3449.303","article-title":"Immunological tolerance","volume":"133","author":"Medawar","year":"1961","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2017.11.018_bb0100","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejpb.2014.11.013","article-title":"Analysis of the absorption kinetics of macromolecules following intradermal and subcutaneous administration","volume":"89","author":"Milewski","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"12","key":"10.1016\/j.ebiom.2017.11.018_bb0105","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.cgh.2007.08.013","article-title":"HLA DQ gene dosage and risk and severity of celiac disease","volume":"5","author":"Murray","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ebiom.2017.11.018_bb0110","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.4049\/jimmunol.160.10.4719","article-title":"Direct evidence that functionally impaired CD4+ T cells persist in vivo following induction of peripheral tolerance","volume":"160","author":"Pape","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.ebiom.2017.11.018_bb0115","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1073\/pnas.0608610104","article-title":"Tetramer visualization of gut-homing gluten-specific T cells in the peripheral blood of celiac disease patients","volume":"104","author":"R\u00e1ki","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ebiom.2017.11.018_bb0120","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.coi.2010.08.006","article-title":"Antigen-specific immunotherapy of autoimmune and allergic diseases","volume":"22","author":"Sabatos-Peyton","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ebiom.2017.11.018_bb0125","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nrgastro.2015.156","article-title":"Practical insights into gluten-free diets","volume":"12","author":"See","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ebiom.2017.11.018_bb0130","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nri3407","article-title":"Triggers and drivers of autoimmunity: lessons from coeliac disease","volume":"13","author":"Sollid","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ebiom.2017.11.018_bb0135","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000093","article-title":"Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS","volume":"2","author":"Streeter","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.ebiom.2017.11.018_bb0140","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF01535722","article-title":"GSRS \u2013 a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease","volume":"33","author":"Svedlund","year":"1988","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ebiom.2017.11.018_bb0145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001012","article-title":"Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease","volume":"2","author":"Tye-Din","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ebiom.2017.11.018_bb0150","first-page":"A26","article-title":"Gluten ingestion and intradermal injection of peptides that activate gluten-specific CD4+ T cells elicit a cytokine signature dominated by interleukin-2 in celiac disease","volume":"5","author":"Tye-Din","year":"2017","journal-title":"United European Gastroenterol. J."}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396417304619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396417304619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T23:45:53Z","timestamp":1693266353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396417304619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":30,"alternative-id":["S2352396417304619"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2017.11.018","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2017.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}